It is possible that one of these drugs might suit a particular individual better than another. A specialist may be able to advise whether there is any advantage associated with a particular drug.
At present, AchIs are used only in people with mild to moderate Alzheimer's disease. They are not effective for everyone and may only temporarily improve memory or delay memory loss. Research is being undertaken to find out whether any of these drugs may be effective in the later stages of Alzheimer's disease. 3 In 
Memantine
The action of memantine is different from that of the AchIs. Memantine blocks another neurotransmitter in the brain known as glutamate.
Glutamate is released in excessive amounts when brain cells are damaged by Alzheimer's disease, causing the brain cells to be damaged further.
Memantine is thought to protect brain cells by blocking this release of excess glutamate.
Memantine can temporarily slow down the progression of symptoms in people in the middle and later stages of the disease. This is the first time a drug has been available for this group of people. There is also a suggestion that memantine may slow down the disease process itself. 4 At first, memantine was licensed for the treatment of moderately severe to severe Alzheimer's disease, but, following a positive opinion from the CHMP of the EMEA in October 2005, the European Commission granted memantine an extension of the indication to the treatment of patients with moderate to severe Alzheimer's disease.
Inequalities in Access to Alzheimer Treatments in Europe
In its Strategic Plan (2006-10), Alzheimer Europe has provided a clear mission statement for its work. Its core objective is defined as "changing perceptions, policy and practice in order to improve the access by people with dementia and their carers to treatment options and care services".
Access by European citizens to existing antidementia drugs is, of course, a key concern of Alzheimer associations throughout Europe. In 2005 and 2006, Alzheimer Europe co-ordinated a response of its national organisations to the appraisal document of the National Institute for Health and Clinical Excellence (NICE) in the UK on the treatments available for Alzheimer's disease. In its response, the organisations expressed their grave concern about the proposal to limit access of UK citizens to treatments that are available to people with Alzheimer's disease in other European countries. 
The Reimbursement of Alzheimer Treatments in Europe
Reimbursement systems in Europe vary quite considerably, but each European country has a system in place that guarantees that essential medicines are made available to patients at an affordable price that is at least partly underwritten by the national health systems. 7 It is therefore not surprising that a recent article 8 warned about the "alarming arbitrariness" of these prescription and reimbursement criteria in Europe (see Table 2 ).
Market Access Delays
A final aspect that Alzheimer Europe covered in its survey on the availability of antidementia drugs concerned the dates of market authorisation, product launches and reimbursement decisions in the different countries. While differences in market authorisations already point to significant delays in some countries for the approval of new medicines, these delays are further exacerbated by the time it takes for pricing decisions to be made and for products to be launched, as well as for new treatments to be included in the reimbursement system. Table 3 shows the delays experienced in some countries for market authorisation, launch or reimbursement decisions for three of the Alzheimer medicines.
Although it was impossible to find data for all the countries covered in our survey, the findings point to significant delays in some countries as to the access of people with Alzheimer's disease to treatment options available to patients in other countries. With the decision to centralise market authorisations for drugs for the treatment of neurodegenerative diseases -such as Alzheimer's disease -at the level of the EMEA, the delays between the Member States of the EU will disappear.
Nevertheless, due to pricing discussions in some countries or internal company decisions, the launch dates of products will continue to vary and some people with Alzheimer's disease will have earlier access to new treatments than others.
Similarly, true access to antidementia drugs is obtained by patients only once these drugs are part of the reimbursement system, as otherwise treatment with these drugs may be limited only to those people who can afford to pay for them themselves. As can be seen from Table 3 , although rivastigmine was authorised through the centralised procedure with European-wide marketing authorisation on 12 May 1998, there were significant differences as to the dates on which individual countries included this treatment in their reimbursement systems.
For Alzheimer Europe, these differences are unacceptable, and the organisation is campaigning for people with Alzheimer's disease throughout Europe to have equal access to a high standard of care services and treatment options.
Treatment Rates
The Alzheimer Europe survey shows important differences between showed that a majority of physicians recommended treatment at the time of diagnosis. Nevertheless, there were marked differences between countries, with UK carers reporting that treatment was recommended at the time of diagnosis in only 51% of cases, whereas carers in Poland or Spain reported that this was the case in 86% of cases.
As to the treatment recommended, carers reported mainly prescription 
YOU CAN ALSO SIGN THE DECLARATION ONLINE:
So please help us now to make dementia a public health priority by signing our declaration. Similarly, a recent study by Waldemar et al. 18 calculated the rates of people with Alzheimer's disease who receive treatment by combining the Alzheimer Europe prevalence rates with data obtained from international marketing services about the sales of donepezil, galantamine, rivastigmine and memantine (see Table 4 ).
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Conclusions
The Alzheimer Europe survey and other studies in this field confirm that people with Alzheimer's disease do not have equal access to existing dementia treatments in Europe. Rather, access is subject to a great many restrictions and there are huge variations in access between European countries. ■ Alzheimer's Disease 
